Which statement best reflects the sponsor's requirements when planning clinical trials?

• A. The trials should be designed to test the sponsor's financial performance.
• B. Sufficient safety and efficacy data are available to support human exposure by the route, at the dosages, for the duration, and in the trial population to be studied.
• C. All trial activities must be outsourced to third parties.
• D. No prior safety data is required if the trial is short.

Answer: (B)

Before a clinical trial begins, the sponsor must ensure there is enough safety and efficacy data to justify exposing humans to the investigational product through the planned route, at the chosen doses, for the expected duration, and in the population to be studied. This provides a solid scientific and ethical basis for the trial, showing that risks have been considered and are likely manageable given the proposed exposure. It reflects the responsibility to protect participants by grounding the study design in known data about how the product behaves in the body and what adverse effects might occur, across the specific route, dose, duration, and patient group.

This means data from nonclinical studies and any existing human data should support the planned exposure, so the risk/benefit balance is reasonable before enrolling participants. Other options miss this core requirement: focusing on financial motives does not address participant safety or scientific validity; mandating outsourcing of all activities is not a universal rule; and claiming no prior safety data are needed for short trials ignores fundamental ethical and regulatory expectations that some safety data are always necessary before human exposure.